Misonix Approved as Surgical Tool
The Food and Drug Administration (FDA) has granted 510 (k) clearance for the marketing and selling of Misonix’s Sonatherm 600 Ultrasonic Lesion Generating System.
The Sonatherm System utilizes High Intensity Focused Ultrasound (HIFU) technology licensed from Focus Surgery for ablation of certain soft tissue lesions in general surgery procedures. The treatment, which utilizes concentrated acoustic waves for ablation may be performed either laparoscopically or through intraoperative procedures.
© 1998-2007 OncoEd.com All Rights Reserved.
These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers should verify all information and data before administering any drug, therapy or treatment discussed herein. Neither the editors nor the publisher accepts any responsibility for the accuracy of the information or consequences from the use or misuse of the information contained herein.
Patient Home
